$CDNA News
Last published 5d ago
- 5d agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of ...
- 1w agoCDNACareDx, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoCDNACareDx Announces Third Quarter 2026 Financial ResultsBusiness WireThird Quarter Revenue Growth of 39% to $139 Million Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million CareDx, Inc. (NASDAQ:CDNA) — a leading
- 2w agoCDNACareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026Business WireIn an independent randomized trial, AlloSure-based monitoring demonstrates a significant reduction in kidney transplant biopsies while maintaining similar clinical outcomes A multinational study shows AlloSure Kidney
- 3w agoCDNACareDx to Report Third Quarter 2026 Financial Results on October 29, 2026Business WireCareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after
- 3mo agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCareDx, Inc. (NASDAQ:CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s
- 3mo agoCDNACareDx Announces Second Quarter 2026 Financial ResultsBusiness WireSecond Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million CareDx, Inc. (NASDAQ:CDNA) — a
- 3mo agoCDNACareDx to Report Second Quarter 2026 Financial Results on July 30, 2026Business WireCareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after
- 3mo agoCDNACareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage DeterminationBusiness WireCoverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty
- 4mo agoCDNACareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty OncologyBusiness WireNavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell
- 4mo agoCDNACareDx Announces Completion of Sale of Lab Products Business to Eurobio ScientificBusiness WireSharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery,
- 4mo agoCDNACareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant CongressBusiness WireGrowing body of evidence supports AlloSure® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes Data across kidney, heart, lung, and multi-organ transplantation; featuring
- 4mo agoCDNACareDx Announces Second KOAR Analysis Published in the Journal of the American Society of NephrologyBusiness WireAlloSure® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data support the role of AlloSure® Kidney as a noninvasive tool for longitudinal
- 5mo agoCDNACareDx to Participate in Upcoming Investor ConferencesBusiness WireCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare
- 6mo agoCDNACareDx Announces Dismissal of 2021 Qui Tam SuitBusiness WireCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 6mo agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 6mo agoCDNACareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance TestingBusiness WireTransaction extends CareDx's Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue
- 6mo agoCDNACareDx Announces First Quarter 2026 Financial ResultsBusiness WireFirst Quarter Revenue Growth of 39% Driven by Strong Performance Across Testing Services and Patient and Digital Solutions Raises 2026 Revenue Guidance to $447 Million to $465 Million and Raises 2026 AEBITDA Guidance
- 6mo agoCDNACareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual MeetingBusiness WireBreadth of Data Demonstrates the Important Role of Precision Medicine Testing in Post-Transplant Monitoring and Decision Making New SHORE Data Highlights Significance of Early Molecular Signals in Heart Transplant and
- 6mo agoCDNACareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read SequencingBusiness WireAlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories. CareDx, Inc. (NASDAQ:CDNA) — The
- 7mo agoCDNACareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial ResultsBusiness WireTransaction Expected to Sharpen CareDx's Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA Margin
- 7mo agoCDNACareDx to Report First Quarter 2026 Financial Results on April 28, 2026Business WireCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 8mo agoCDNACareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant DatasetsBusiness WireFirst-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference CareDx, Inc.
- 8mo agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 8mo agoCDNACareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial OfficerBusiness WireKennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and
- 8mo agoCDNACareDx Announces Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireFull Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading
- 8mo agoCDNACareDx to Participate in the Raymond James 47th Annual Institutional Investors ConferenceBusiness WireCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare
- 9mo agoCDNACareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell TherapyBusiness WireAlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the
- 9mo agoCDNACareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Business WireCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare
- 9mo agoCDNACareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem MeetingsBusiness WireCompany to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation data and review commercial launch timeline CareDx, Inc.
- 10mo agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 10mo agoCDNACareDx Provides Notice of Proposed Derivative SettlementBusiness WireCareDx, Inc. (NASDAQ:CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JEFFREY EDELMAN, JAYSEN Case No.
- 11mo agoCDNASHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung TransplantationBusiness WireThird SHORE Publication Highlights HeartCare's Role in Risk Stratification and Personalized Post-Transplant Care CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine company focused on the discovery, development,
- 1y agoCDNACareDx to Participate in Upcoming Investor ConferencesBusiness WireCareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 1y agoCDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 1y agoCDNACareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025Business WireCareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading
- 1y agoCDNACareDx Announces Third Quarter 2025 Financial ResultsBusiness WireTotal Revenue of $100 Million Increased 21% Year-Over-Year Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year Raised 2025 Revenue Guidance to $372 Million to $376 Million CareDx,
- 1y agoCDNACareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical OfficerBusiness WireRenowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and
- 1y agoCDNACareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart FailureBusiness WireSecond SHORE Study Validates AlloSure Heart, an Integral Component of HeartCare, as a Reliable Biomarker for Antibody-Mediated Rejection in Heart Transplant Recipients CareDx, Inc. (NASDAQ:CDNA) – a leading precision
- 1y agoCDNACareDx Announces Appointment of Suresh Gunasekaran to Board of DirectorsBusiness WireCareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today
- 1y agoCDNACareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual MeetingBusiness WireFurthers Global Leadership in Donor Organ and Transplant Recipient HLA Typing CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development,
- 1y agoCDNACareDx Issues Comment Letter on Draft LCD PolicyBusiness WireCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 1y agoCDNACareDx to Participate in Wells Fargo Healthcare ConferenceBusiness WireCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 1y agoCDNACareDx, Inc (CDNA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCDNACareDx Announces Appointment of Nathan Smith as Chief Financial OfficerBusiness WireCareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
- 1y agoCDNACareDx Announces Second Quarter 2025 Financial ResultsBusiness WireGrew Testing Services Volume to Approximately 49,500, Increase of 13% Year-Over-Year AlloSure Kidney Testing Volumes Grew Nearly 20% Year-Over-Year Narrows Full Year 2025 Revenue Guidance to $367 Million to $373
- 1y agoCDNACareDx Announces Landmark KOAR Study Published in the American Journal of TransplantationBusiness WireKOAR, the Largest Prospective Study of Its Kind, Demonstrates Clinical Utility of AlloSure® in Kidney Transplant Surveillance AlloSure Kidney dd-cfDNA Elevation Strongly Predicts Rejection and Improves Biopsy
- 1y agoCDNACareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant CongressBusiness WireAnnounces the Launch of AlloSure® Plus Integrated into EPIC Aura CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and
- 1y agoCDNACareDx to Report Second Quarter 2025 Financial ResultsBusiness WireCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and
- 1y agoCDNACareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant RejectionBusiness WireDraft Policy Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision